G1 Therapeutics, Inc. (NASDAQ:GTHX – Free Report) – Investment analysts at HC Wainwright reduced their FY2026 earnings estimates for shares of G1 Therapeutics in a research report issued to clients and investors on Thursday, May 2nd. HC Wainwright analyst E. White now expects that the company will post earnings of $0.72 per share for the […]
G1 Therapeutics (NASDAQ:GTHX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at Needham & Company LLC in a research note issued on Wednesday, Benzinga reports. They presently have a $12.00 price target on the stock. Needham & Company LLC’s price objective would suggest a potential upside of 214.96% from […]
abrdn plc bought a new position in G1 Therapeutics, Inc. (NASDAQ:GTHX – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 423,869 shares of the company’s stock, valued at approximately $1,293,000. abrdn plc owned about 0.82% of G1 Therapeutics at the end […]